#None #Psoriasis #AbbVie #Skyrizi

AbbVie's SKYRIZI® Approved for Pediatric Use in Europe

AbbVie has proudly announced the European Commission's approval for SKYRIZI® (risankizumab), allowing its use among children and adolescents aged six years and older who suffer from moderate to severe plaque psoriasis. This progressive step aims to cater to a significant medical need, as nearly a third of individuals with psoriasis show symptoms before high school, often affecting visible areas of the skin, which can lead to social stigma and school absenteeism.

The latest approval includes a new 55 mg pre-filled syringe designed for weight-based dosing in children weighing less than 40 kg. This specialized dosing option demonstrates AbbVie's commitment to providing tailored treatments for younger patients. Roopal Thakkar, M.D., executive vice president, underscored the importance of this approval, highlighting that it brings much-needed options for managing a condition that can significantly impact a child's quality of life.

Understanding the Impact of Pediatric Psoriasis

Pediatric psoriasis often presents unique challenges due to its visibility and impact on social interactions. It is crucial to address these challenges effectively at an early stage to prevent long-term psychological impacts and improve the overall well-being of children affected by this disease. Despite the severity of the condition, it has been noted that nearly 70% of young patients rely solely on topical therapies, emphasizing the necessity of more comprehensive treatment options.

The European Commission's endorsement of SKYRIZI is grounded in pivotal data from the Phase 3 OptIMMize-1 and OptIMMize-2 clinical trials. These trials included a variety of study cohorts, assessing both safety and efficacy in younger populations. Notably, the results demonstrated that pediatric patients responded favorably to SKYRIZI, with an observed safety profile similar to that seen in adults with moderate to severe psoriasis. No new significant safety concerns were noted, affirming the treatment’s suitability for children.

Dr. Nina Magnolo from the Department of Dermatology at the University Hospital of Münster, and an investigator for the OptIMMize-1 study, stated that early management can dramatically enhance a child’s quality of life and curb the potential worsening of symptoms. The approval of SKYRIZI provides a much-needed alternative for pediatric patients navigating psoriasis management.

About SKYRIZI® and Its Mechanism

SKYRIZI functions as an interleukin-23 (IL-23) inhibitor, a specific regulator involved in inflammatory responses, making it a vital tool in the treatment of various immune-mediated diseases. Aside from its use in pediatric psoriasis, SKYRIZI has also been authorized for adult applications in plaque psoriasis, psoriatic arthritis, and conditions like Crohn's disease and ulcerative colitis.

AbbVie maintains a commitment to pushing forward immunology treatment options, and SKYRIZI's approval for pediatric treatment signifies an essential advancement towards improving the quality of life for younger patients living with chronic inflammatory conditions. As a company dedicated to enhancing healthcare, AbbVie continues to innovate and explore new pathways that empower patients and build healthier futures.

Conclusion

The recent approval of SKYRIZI by the European Commission marks a significant milestone for pediatric psoriasis treatment options. As AbbVie expands its focus on immunology, this step promises to provide effective therapy alternatives tailored to the unique needs of children combating the implications of this chronic skin condition. With this approval, healthcare providers can now offer a more rounded approach to managing plaque psoriasis in pediatric populations, aiming for better health outcomes and life quality for younger patients grappling with this challenging disease.